In the present study, we aimed to find a novel therapy for ccRCC and verified that down-regulating LINC01094 could increase miR-184 expression and inhibit SLC2A3 expression, thereby curtailing the development of ccRCC. This evidence concerns the gene LINC01094 and nonpapillary renal cell carcinoma.